Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 13/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 13/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.37 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.37 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4028021 | 0.90 | ESR1 (0.52) | ESR1ESR2NR1H2NR1H3NR1I2 | |
| SCHEMBL4026814 | 0.88 | CYP1A1 (0.39) | CYP1A2CYP3A4CYP2C19CYP1A1CYP2E1 | |
| SCHEMBL1407562 | 0.85 | NR1H2 (0.42) | NR1H2NR1H3NR1I2NR3C1AR | |
| SCHEMBL1407378 | 0.84 | NR1H2 (0.42) | NR1H2NR1H3NR1I2NR3C1AR | |
| SCHEMBL4027876 | 0.84 | NR1H2 (0.54) | ESR1ESR2NR1H2NR1H3NR1I2 | |
| SCHEMBL29817411 | 0.83 | ESR1 (0.64) | ESR1ESR2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL1407260 | 0.83 | NR1H2 (0.40) | NR1H2NR1H3NR1I2NR3C1AR | |
| SCHEMBL3889569 | 0.83 | ESR1 (0.64) | ESR1ESR2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL1407269 | 0.81 | GRM2 (0.42) | NR1H2NR1H3NR1I2NR3C1AR | |
| SCHEMBL4030256 | 0.79 | ESR1 (0.67) | ESR1ESR2NR1H2NR1H3NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773781-A2 | INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES | Wyeth (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006017384-A2 | INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES | WYETH (US) | 2006-02-16 | — | — | WO | claimed |
| US-20060030612-A1 | Indazoles useful in treating cardiovascular diseases | WYETH (US) | 2006-02-09 | — | — | US | claimed |
| EP-2295429-A1 | 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases | Wyeth LLC (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7601847-B2 | Via lithium bis(trimethylsilyl)amide, lithium dicyclohexylamide, or potassium bis(trimethylsilyl)amide base and alkylating agent; atherosclerosis, myocardial infarction, congestive heart failure, inflammatory bowel disease, arthritis, type II diabetes, multiple sclerosis and rheumatoid arthritis | WYETH (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601847-B2 | Via lithium bis(trimethylsilyl)amide, lithium dicyclohexylamide, or potassium bis(trimethylsilyl)amide base and alkylating agent; atherosclerosis, myocardial infarction, congestive heart failure, inflammatory bowel disease, arthritis, type II diabetes, multiple sclerosis and rheumatoid arthritis | WYETH (US) | 2009-10-13 | — | — | US | disclosed |
| US-7592363-B2 | Indazoles | WYETH (US) | 2009-09-22 | — | — | US | disclosed |
| EP-1542976-B1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH CORP (US) | 2009-02-04 | — | — | EP | disclosed |
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7241791-B2 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1773781-A2 | INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES | Wyeth (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006017384-A2 | INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES | WYETH (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20060030612-A1 | Indazoles useful in treating cardiovascular diseases | WYETH (US) | 2006-02-09 | — | — | US | disclosed |
| EP-1542976-A1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | Wyeth (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2004-08-26 | — | — | US | disclosed |
| WO-2004031159-A1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030612-A1 | Indazoles useful in treating cardiovascular diseases | NR1H2, NR1H3, CYP46A1 | ESR1 840/4885ESR2 236/4885NR1H2 1/4885 |
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | INSR, TNNI3, INSRR | ESR1 1028/4885ESR2 621/4885NR1H2 368/4885 |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | INSR, MSR1, TNNI3 | ESR1 2487/4885ESR2 605/4885NR1H2 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.